Chronic Heart Failure: Contemporary Diagnosis and Management
Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prev...
Gespeichert in:
Veröffentlicht in: | Mayo Clinic proceedings 2010-02, Vol.85 (2), p.180-195 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 195 |
---|---|
container_issue | 2 |
container_start_page | 180 |
container_title | Mayo Clinic proceedings |
container_volume | 85 |
creator | Ramani, Gautam V., MD Uber, Patricia A., Pharm D Mehra, Mandeep R., MBBS |
description | Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prevention of coronary artery disease and risk factor management via aggressive blood pressure control are central in preventing new occurrences of left ventricular dysfunction. Optimal therapy for CHF involves identification and correction of potentially reversible precipitants, target-dose titration of medical therapy, and management of hospitalizations for decompensation. The etiological phenotype, absolute decrease in left ventricular ejection fraction and a widening of QRS duration on electrocardiography, is commonly used to identify patients at increased risk of progression of heart failure and sudden death who may benefit from prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Patients who transition to advanced stages of disease despite optimal traditional medical and device therapy may be candidates for hemodynamically directed approaches such as a left ventricular assist device; in selected cases, listing for cardiac transplant may be warranted. |
doi_str_mv | 10.4065/mcp.2009.0494 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2813829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A219146024</galeid><els_id>S0025619611603935</els_id><sourcerecordid>A219146024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c682t-e0be52ddb1f389c4a2228d28c32641927337bf055ca4a16e8fe9b37477e473023</originalsourceid><addsrcrecordid>eNp1kt9rFDEQx4Mo9jx99FUWQX3aM7822RQplNNaoeKD-hyy2dm71N3kTHYL_e_NcufZFiQPgeQzM9-Z7yD0kuAVx6J6P9jdimKsVpgr_ggtiOK0rCouHqMFxrQqBVHiBD1L6RpjLJXiT9EJxYTUTFUL9GG9jcE7W1yCiWNxYVw_RTgt1sGPMOxCNPG2-OjMxofkUmF8W3w13mxgAD8-R0860yd4cbiX6OfFpx_ry_Lq2-cv6_Or0oqajiXgBiratg3pWK0sN5TSuqW1ZVRwoqhkTDYdripruCEC6g5UwySXErhkmLIlOtvn3U3NAK3NpaPp9S66IcvTwTh9_8e7rd6EG01rwmqqcoJ3hwQx_J4gjXpwyULfGw9hSjorqKQiTGby9QPyOkzR5-40JaKWAufBLdFqD21MD9r5LuSqNp8WBmeDh87l93NKFOECU54D3t4J2ILpx20K_TS64NN9sNyDNoaUInTHJgnWs986-61nv_Xsd-Zf3Z3Mkf5rcAbeHACTrOm7aLx16R9HmeBczC3JPQfZxxsHUSfrwFtoXQQ76ja4_0o4exBpe5c3yvS_4BbScXxEJ6qx_j4v5byThAjMFKvYHxQ92DQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216876018</pqid></control><display><type>article</type><title>Chronic Heart Failure: Contemporary Diagnosis and Management</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Ramani, Gautam V., MD ; Uber, Patricia A., Pharm D ; Mehra, Mandeep R., MBBS</creator><creatorcontrib>Ramani, Gautam V., MD ; Uber, Patricia A., Pharm D ; Mehra, Mandeep R., MBBS</creatorcontrib><description>Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prevention of coronary artery disease and risk factor management via aggressive blood pressure control are central in preventing new occurrences of left ventricular dysfunction. Optimal therapy for CHF involves identification and correction of potentially reversible precipitants, target-dose titration of medical therapy, and management of hospitalizations for decompensation. The etiological phenotype, absolute decrease in left ventricular ejection fraction and a widening of QRS duration on electrocardiography, is commonly used to identify patients at increased risk of progression of heart failure and sudden death who may benefit from prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Patients who transition to advanced stages of disease despite optimal traditional medical and device therapy may be candidates for hemodynamically directed approaches such as a left ventricular assist device; in selected cases, listing for cardiac transplant may be warranted.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.4065/mcp.2009.0494</identifier><identifier>PMID: 20118395</identifier><identifier>CODEN: MACPAJ</identifier><language>eng</language><publisher>Rochester, MN: Elsevier Inc</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Calcium Channel Blockers - therapeutic use ; Cardiology. Vascular system ; Cardiotonic Agents - therapeutic use ; Care and treatment ; Chronic Disease ; Defibrillators, Implantable ; Development and progression ; Diagnosis ; General aspects ; Health Expenditures - trends ; Heart ; Heart failure ; Heart Failure - diagnosis ; Heart Failure - economics ; Heart Failure - epidemiology ; Heart Failure - etiology ; Heart Failure - therapy ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Transplantation ; Heart-Assist Devices ; Hospitalization - trends ; Humans ; Internal Medicine ; Mass Screening ; Medical sciences ; Prevalence ; Primary Prevention ; Prognosis ; Risk factors ; Symposium on Cardiovascular Diseases ; Vasodilator Agents - therapeutic use</subject><ispartof>Mayo Clinic proceedings, 2010-02, Vol.85 (2), p.180-195</ispartof><rights>Mayo Foundation for Medical Education and Research</rights><rights>2010 Mayo Foundation for Medical Education and Research</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2010 Elsevier, Inc.</rights><rights>Copyright Mayo Foundation for Medical Education and Research Feb 2010</rights><rights>2010 Mayo Foundation for Medical Education and Research 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c682t-e0be52ddb1f389c4a2228d28c32641927337bf055ca4a16e8fe9b37477e473023</citedby><cites>FETCH-LOGICAL-c682t-e0be52ddb1f389c4a2228d28c32641927337bf055ca4a16e8fe9b37477e473023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813829/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813829/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22364468$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20118395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramani, Gautam V., MD</creatorcontrib><creatorcontrib>Uber, Patricia A., Pharm D</creatorcontrib><creatorcontrib>Mehra, Mandeep R., MBBS</creatorcontrib><title>Chronic Heart Failure: Contemporary Diagnosis and Management</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prevention of coronary artery disease and risk factor management via aggressive blood pressure control are central in preventing new occurrences of left ventricular dysfunction. Optimal therapy for CHF involves identification and correction of potentially reversible precipitants, target-dose titration of medical therapy, and management of hospitalizations for decompensation. The etiological phenotype, absolute decrease in left ventricular ejection fraction and a widening of QRS duration on electrocardiography, is commonly used to identify patients at increased risk of progression of heart failure and sudden death who may benefit from prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Patients who transition to advanced stages of disease despite optimal traditional medical and device therapy may be candidates for hemodynamically directed approaches such as a left ventricular assist device; in selected cases, listing for cardiac transplant may be warranted.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiology. Vascular system</subject><subject>Cardiotonic Agents - therapeutic use</subject><subject>Care and treatment</subject><subject>Chronic Disease</subject><subject>Defibrillators, Implantable</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>General aspects</subject><subject>Health Expenditures - trends</subject><subject>Heart</subject><subject>Heart failure</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - economics</subject><subject>Heart Failure - epidemiology</subject><subject>Heart Failure - etiology</subject><subject>Heart Failure - therapy</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heart Transplantation</subject><subject>Heart-Assist Devices</subject><subject>Hospitalization - trends</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Mass Screening</subject><subject>Medical sciences</subject><subject>Prevalence</subject><subject>Primary Prevention</subject><subject>Prognosis</subject><subject>Risk factors</subject><subject>Symposium on Cardiovascular Diseases</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kt9rFDEQx4Mo9jx99FUWQX3aM7822RQplNNaoeKD-hyy2dm71N3kTHYL_e_NcufZFiQPgeQzM9-Z7yD0kuAVx6J6P9jdimKsVpgr_ggtiOK0rCouHqMFxrQqBVHiBD1L6RpjLJXiT9EJxYTUTFUL9GG9jcE7W1yCiWNxYVw_RTgt1sGPMOxCNPG2-OjMxofkUmF8W3w13mxgAD8-R0860yd4cbiX6OfFpx_ry_Lq2-cv6_Or0oqajiXgBiratg3pWK0sN5TSuqW1ZVRwoqhkTDYdripruCEC6g5UwySXErhkmLIlOtvn3U3NAK3NpaPp9S66IcvTwTh9_8e7rd6EG01rwmqqcoJ3hwQx_J4gjXpwyULfGw9hSjorqKQiTGby9QPyOkzR5-40JaKWAufBLdFqD21MD9r5LuSqNp8WBmeDh87l93NKFOECU54D3t4J2ILpx20K_TS64NN9sNyDNoaUInTHJgnWs986-61nv_Xsd-Zf3Z3Mkf5rcAbeHACTrOm7aLx16R9HmeBczC3JPQfZxxsHUSfrwFtoXQQ76ja4_0o4exBpe5c3yvS_4BbScXxEJ6qx_j4v5byThAjMFKvYHxQ92DQ</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Ramani, Gautam V., MD</creator><creator>Uber, Patricia A., Pharm D</creator><creator>Mehra, Mandeep R., MBBS</creator><general>Elsevier Inc</general><general>Mayo Foundation</general><general>Elsevier, Inc</general><general>Elsevier Limited</general><general>Mayo Foundation for Medical Education and Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4U-</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100201</creationdate><title>Chronic Heart Failure: Contemporary Diagnosis and Management</title><author>Ramani, Gautam V., MD ; Uber, Patricia A., Pharm D ; Mehra, Mandeep R., MBBS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c682t-e0be52ddb1f389c4a2228d28c32641927337bf055ca4a16e8fe9b37477e473023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiology. Vascular system</topic><topic>Cardiotonic Agents - therapeutic use</topic><topic>Care and treatment</topic><topic>Chronic Disease</topic><topic>Defibrillators, Implantable</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>General aspects</topic><topic>Health Expenditures - trends</topic><topic>Heart</topic><topic>Heart failure</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - economics</topic><topic>Heart Failure - epidemiology</topic><topic>Heart Failure - etiology</topic><topic>Heart Failure - therapy</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heart Transplantation</topic><topic>Heart-Assist Devices</topic><topic>Hospitalization - trends</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Mass Screening</topic><topic>Medical sciences</topic><topic>Prevalence</topic><topic>Primary Prevention</topic><topic>Prognosis</topic><topic>Risk factors</topic><topic>Symposium on Cardiovascular Diseases</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramani, Gautam V., MD</creatorcontrib><creatorcontrib>Uber, Patricia A., Pharm D</creatorcontrib><creatorcontrib>Mehra, Mandeep R., MBBS</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramani, Gautam V., MD</au><au>Uber, Patricia A., Pharm D</au><au>Mehra, Mandeep R., MBBS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic Heart Failure: Contemporary Diagnosis and Management</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>85</volume><issue>2</issue><spage>180</spage><epage>195</epage><pages>180-195</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><coden>MACPAJ</coden><abstract>Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prevention of coronary artery disease and risk factor management via aggressive blood pressure control are central in preventing new occurrences of left ventricular dysfunction. Optimal therapy for CHF involves identification and correction of potentially reversible precipitants, target-dose titration of medical therapy, and management of hospitalizations for decompensation. The etiological phenotype, absolute decrease in left ventricular ejection fraction and a widening of QRS duration on electrocardiography, is commonly used to identify patients at increased risk of progression of heart failure and sudden death who may benefit from prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Patients who transition to advanced stages of disease despite optimal traditional medical and device therapy may be candidates for hemodynamically directed approaches such as a left ventricular assist device; in selected cases, listing for cardiac transplant may be warranted.</abstract><cop>Rochester, MN</cop><pub>Elsevier Inc</pub><pmid>20118395</pmid><doi>10.4065/mcp.2009.0494</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-6196 |
ispartof | Mayo Clinic proceedings, 2010-02, Vol.85 (2), p.180-195 |
issn | 0025-6196 1942-5546 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2813829 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Adrenergic beta-Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antihypertensive Agents - therapeutic use Biological and medical sciences Calcium Channel Blockers - therapeutic use Cardiology. Vascular system Cardiotonic Agents - therapeutic use Care and treatment Chronic Disease Defibrillators, Implantable Development and progression Diagnosis General aspects Health Expenditures - trends Heart Heart failure Heart Failure - diagnosis Heart Failure - economics Heart Failure - epidemiology Heart Failure - etiology Heart Failure - therapy Heart failure, cardiogenic pulmonary edema, cardiac enlargement Heart Transplantation Heart-Assist Devices Hospitalization - trends Humans Internal Medicine Mass Screening Medical sciences Prevalence Primary Prevention Prognosis Risk factors Symposium on Cardiovascular Diseases Vasodilator Agents - therapeutic use |
title | Chronic Heart Failure: Contemporary Diagnosis and Management |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A14%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20Heart%20Failure:%20Contemporary%20Diagnosis%20and%20Management&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Ramani,%20Gautam%20V.,%20MD&rft.date=2010-02-01&rft.volume=85&rft.issue=2&rft.spage=180&rft.epage=195&rft.pages=180-195&rft.issn=0025-6196&rft.eissn=1942-5546&rft.coden=MACPAJ&rft_id=info:doi/10.4065/mcp.2009.0494&rft_dat=%3Cgale_pubme%3EA219146024%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216876018&rft_id=info:pmid/20118395&rft_galeid=A219146024&rft_els_id=S0025619611603935&rfr_iscdi=true |